NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board

Company Broadens Scientific Expertise with Addition of Mental Health Expert in Setting Up and Managing Interventional Psychiatric Clinics

VANCOUVER, BC / ACCESSWIRE / September 16, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FSE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today the appointment of Dr. Roumen Milev, MD, PhD, Clinical Lead of Providence Care Hospital Interventional Psychiatry to its Specialty Clinics Advisory Board. Providence Care Hospital is one of Ontario's leading providers of specialized care in aging, mental health, and rehabilitation and is fully affiliated with Queen's University and St. Lawrence College, and an esteemed member of the Council of Academic Hospitals of Ontario, Canada.

In his role on NeonMind's Specialty Clinics Advisory Board, Dr. Milev will leverage his vast experience and success in setting up and managing interventional psychiatry clinics to support NeonMind as it develops its company-branded, specialty clinics network to enhance access to evidence-backed effective treatments including ketamine.

Dr. Milev leads the Interventional Psychiatry Clinic at Providence Care Hospital in Kingston, Ontario and has overseen more than 1,000 patients successfully treated with ketamine and neurostimulation modalities. He was appointed the Clinical Director of the Mood Disorder Research and Treatment Service in Kingston in 2001. From 2007 until 2017, he was the Head of the Department of Psychiatry at Queen's University. In 2017, he became the Director of Centre for Neuroscience Studies at Queen's University and in 2018, he was appointed as Vice President, Medical and Academic Affairs at Providence Care Hospital. He is the current Executive Chair Elect of the Canadian Network for Mood and Anxiety Treatments (CANMAT) and an Executive Committee Member of the Canadian Biomarker Integration Network for Depression (CAN-BIND). He is a Fellow of the Royal College of Psychiatrists (UK), a Distinguished Fellow of both the Canadian and American Psychiatry Associations, a Fellow of the Royal College of Physicians of Canada and defended a PhD in Forensic Psychiatry.

Dr. Milev is actively involved in research in depression, bipolar disorder, and other mental disorders with a strong focus on stigma, sleep architecture, psychopharmacological and neurostimulation treatments as well as, microbiome manipulation for treatment of mood and anxiety disorders. He is the author and editor of over 140 peer-reviewed articles and book chapters and has co-authored multiple CANMAT guidelines for management of patients with Major Depressive Disorder and Bipolar Disorders, the world's most cited mood disorder treatment guidelines as well as CANMAT treatment guidelines including ketamine and neurostimulation.

"Dr. Milev is a global expert in research of novel treatments for mood and anxiety disorders and brings unparalleled experience and leadership expertise in interventional psychiatry which will help support the development and integration of the most successful protocols and treatment modalities for the launch of our specialty clinics. With the addition of Dr. Milev to the clinics board, NeonMind will be well positioned to deliver top notch medical services and programs, bringing access to patients and communities in need," said Robert Tessarolo, President & CEO of NeonMind.

On the importance of interventional psychiatry, Dr. Milev said, "I am very proud of the work our team at Providence Care is doing to have successfully set up and operated our Interventional Psychiatry which is providing important treatment services to patients using ketamine and neurostimulation modalities. There are many opportunities to expand patients' access to these highly effective and safe treatments. I am pleased to be working with NeonMind in developing their network of clinics that is focused on enhancing access to treatments and bringing them into community healthcare."

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company's second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

For more information on NeonMind, go to www.NeonMindBiosciences.com

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101

Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210

Media Inquiries:
KCSA Strategic Communications
Annie Graf
neonmind@kcsa.com
Tel: 786-390-2644

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

SOURCE: NeonMind Biosciences Inc.